Last updated on September 2020

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor


Brief description of study

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).

Clinical Study Identifier: NCT04008797

Find a site near you

Start Over

Eisai Trial Site #3

Osakasayama, Japan
0.01miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.